Dexcom (NSDQ:DXCM) announced today that it launched the new Dexcom One continuous glucose monitoring (CGM) system in the United Kingdom.
San Diego-based Dexcom designed the Dexcom One system as an easy-to-use, real-time CGM (rt-CGM) that it aims to make more affordable and accessible for people with diabetes in the UK.
According to a news release, Dexcom One is currently in review to be added to drug tariffs across the UK regions. Dexcom expects the platform to be made available in the UK next month.
Dexcom One is comprised of a wearable sensor and transmitter that continuously monitors glucose levels and sends real-time values wirelessly to a compatible smart device via the Dexcom One mobile app. Dexcom CEO Kevin Sayer told Drug Delivery Business News earlier this year that Dexcom One represents one of many offerings the company is excited about in 2022.
The company already launched in a handful of European countries at the end of last year. Dexcom One uses the G6 hardware platform with a different software experience, marking the company’s first foray into a differentiated product portfolio. The platform is currently available in Bulgaria, Latvia, Estonia and Lithuania.
“We launched that as an e-commerce platform only and a cash-pay product in those countries with pretty good results,” Sayer said. “It’s a good experience for the individual, and it’s very easy to use. We look at that as a really good expansion opportunity for us, particularly in foreign markets going forward.”
Dexcom said the news follows on the back of new guidance from the National Institute for Health and Care Excellence (NICE) that recommends that adults with type 1 diabetes be offered a choice of glucose sensors, including rt-CGM, based on individual preferences, needs, characteristics and the functionality of the devices available.
NICE also recommends that all children with type 1 diabetes be offered rt-CGM together with education for the children and their families and/or carers on how to use the device.
Dexcom plans to offer Dexcom One in the UK as part of a range of products that includes the Dexcom G6 CGM and the recently CE-marked, next-generation Dexcom G7 system.
“The upcoming launch of Dexcom One represents a significant step forward in diabetes management and inclusion on the drug tariff would ensure that more people benefit from this life-changing technology,” Dexcom VP of UK & Ireland, Benelux, France and Spain Karen Baxter said in the news release. “Should Dexcom One be added to the NHS drug tariff, Dexcom will implement an educational and support program for people with diabetes and healthcare professionals to ensure the diabetes community can benefit as quickly as possible from reimbursement and wider availability of Dexcom CGM.”